Abstract Background Renal cell carcinoma (RCC) is characterized by a highly immunosuppressive tumor microenvironment enriched in tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), both of which correlate with poor clinical outcomes. TAMs in RCC commonly exhibit an immunosuppressive phenotype, marked by...
Giuliana P. Mognol, E. Wang, William Harris et al.· The Oncologist· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
Pancreatic ductal adenocarcinoma is refractory to most therapies, including immunotherapies, where reinvigoration of CD8 T cells with immune checkpoint blockade is insufficient to induce long-term durable remissions. Direct inhibitors of KRAS are clinically promising, although acquired resistance is common. To test i...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cancer Research· 0 citations
It is shown that KRASG12D mutations in lung epithelium drive proliferation of resident, embryonically-derived alveolar macrophages, which then promote tumor cell proliferation and protection from ferroptosis, leading to tumor progression.
Jaroslav Zak, Hui Chen, Erpei Wang et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
